Inc., a clinical-stage biotechnology company specializing in T cell receptor-engineered T cell therapies for cancer treatment, announced that an abstract has been accepted for poster presentation ...

Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases,will be sharing oral and poster presentations at the ...

May 06, 2025--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging ... today announced that three posters were presented at IMMUNOLOGY2025, the annual ...